Skip to main content
. 2023 Mar 16;14:1159912. doi: 10.3389/fmicb.2023.1159912

Figure 1.

Figure 1

In vivo adaptive resistance to carbapenem and ceftazidime/avibactam. In general, acquiring blaKPC harboring-plasmid, and specific mutations in porin genes, such as ompK35 and ompK36, contribute to the development of carbapenem resistance in vivo. Acquiring blaNDM harboring-plasmid, specific mutation in blaKPC and upregulation of blaKPC lead to in vivo ceftazidime/avibactam resistance.